Reports 3Q revenue $3.017M, consensus $120k. “We continued to make solid progress on our strategy execution in a busy third quarter and are very pleased to have achieved several important milestones across our company. The MSD agreement, which holds the potential to transform Evaxion over the coming years, and the groundbreaking EVX-01 phase 2 efficacy data, stand out among our many achievements. We continue to demonstrate our strong capabilities as a truly AI-based TechBio company and remain focused on advancing on-going partnerships as well as new partnership discussions, progressing the EVX-01 trial and carrying through preclinical studies as a basis for expanding our R&D pipeline,” says Christian Kanstrup, CEO of Evaxion.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EVAX:
- Evaxion Biotech to Announce Q3 Financial Results
- Evaxion Biotech’s AI Platform Shows Promising Trial Results
- Evaxion Biotech has evidence from trials validating AI platform prediction
- Evaxion Biotech announces clinical data for AI-Immunology platform
- Evaxion’s AI Platform Boosts Vaccine Target Prediction